GH001

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bipolar II Disorder

Conditions

Bipolar II Disorder

Trial Timeline

Apr 6, 2023 → Dec 5, 2024

About GH001

GH001 is a phase 2 stage product being developed by GH Research for Bipolar II Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT05839509. Target conditions include Bipolar II Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Bipolar II Disorder were approved

Approved (20) Terminated (3) Active (0)
Olanzapine + PlaceboEli LillyApproved
OlanzapineEli LillyApproved
OlanzapineEli LillyApproved
olanzapine + risperidoneEli LillyApproved
Topiramate + PlaceboEli LillyApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05839509Phase 2Terminated
NCT05804708Phase 2Terminated

Competing Products

20 competing products in Bipolar II Disorder

See all competitors
ProductCompanyStageHype Score
OlanzapineEli LillyPhase 3
32
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
40
Olanzapine + PlaceboEli LillyApproved
43
FK949EAstellas PharmaPhase 3
40
FK949EAstellas PharmaPhase 3
40
FK949E + PlaceboAstellas PharmaPhase 2/3
38
Escitalopram + Bupropion XLLupin LimitedPhase 3
32
OlanzapineEli LillyApproved
43
Olanzapine Hydrochloride + Lithium CarbonateEli LillyPhase 3
40
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
40
OlanzapineEli LillyApproved
43
OlanzapineEli LillyPhase 3
40
LY2979165 + PlaceboEli LillyPhase 1
29
olanzapine + divalproex sodium + placeboEli LillyApproved
43
olanzapine + risperidoneEli LillyApproved
43
LY2979165 + placeboEli LillyPhase 1
29
Topiramate + PlaceboEli LillyApproved
43
olanzapineEli LillyPhase 3
40
Olanzapine + PlaceboEli LillyPhase 3
40
Brenipatide + PlaceboEli LillyPhase 2
42